Mumbai: Venus Remedies said on Tuesday its anti-infection drug Sulbactomax has received a European Union patent valid across 37 countries.
The drugmaker expects Sulbactomax to capture 10% market share of the segment in Europe by 2015 with yearly sales reaching €25-30 million.
Sulbactomax, which the firm plans to launch in 2013, is used in the treatment of extended spectrum beta lactamases, it said.
Extended spectrum beta lactamases are enzymes, which bacteria produce to become resistant to widely used anti-biotics.
“In anti-infective segment, the market potential is not that big,” an analyst with a Mumbai-based firm, said.
“In this area, one has to sacrifice margins although sales may rise.”
Venus is considering tie-ups with multinational firms for outlicensing the product in geographies where it holds the patent for sulbactomax, it said.
“This is not a niche product line,” another pharma analyst, who did not wish to be named, said.
Other Indian players like Aurobindo Pharma and Ranbaxy Laboratories have a presence in this segment already, he added.
The firm already holds a patent for this product in India and South Africa, while patent approval is pending from 12 more countries including Japan and US, it said.
At 1:00 p.m., shares of Venus Remedies, which rose more than 4.5% on announcement, were trading at Rs 329, up 3.59% in a firm Mumbai market.